1-8 of 8
Rama Suresh
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Neoadjuvant BMS-813160, nivolumab, gemcitabine and nab-paclitaxel for patients with pancreatic cancer

Patrick M. Grierson, Crystal Wolf, Rama Suresh, Andrea Wang-Gillam, Benjamin R. Tan, Lee Ratner, Peter Oppelt, Olivia Aranha, Ashley Frith, Katrina S. Pedersen, Jennifer Spann, Nicholas Boice, Amberly Brown, John M. Baer, Emily G. Butka, Faiz Ahmad, Yifei Xu, Jingxia Liu, David G. DeNardo, Kian-Huat Lim
Journal: Clinical Cancer Research
Clin Cancer Res (2025)
https://doi.org/10.1158/1078-0432.CCR-24-1821
Published: 24 March 2025
View article titled, Neoadjuvant BMS-813160, nivolumab, gemcitabine and nab-paclitaxel for patients with pancreatic cancer
Open the PDF for Neoadjuvant BMS-813160, nivolumab, gemcitabine and nab-paclitaxel for patients with pancreatic cancer in another window
Includes: Supplementary data
Journal Articles

Detection of circulating tumor DNA using a tissue-free epigenomic assay is a highly prognostic biomarker in early-stage triple negative breast cancer

Foluso O. Ademuyiwa, Cynthia X. Ma, Katherine Weilbaecher, Rama Suresh, Lindsay L. Peterson, Ron Bose, Nusayba Bagegni, Caron E. Rigden, Ashley Frith, Katherine Clifton, Derek Dustin, Mingyang Cai, Liyang Xiong, Sai Chen, Andrew Davis
Journal: Clinical Cancer Research
Clin Cancer Res (2025)
https://doi.org/10.1158/1078-0432.CCR-24-3145
Published: 21 March 2025
View article titled, Detection of circulating tumor DNA using a tissue-free epigenomic assay is a highly prognostic biomarker in early-stage triple negative breast cancer
Open the PDF for Detection of circulating tumor DNA using a tissue-free epigenomic assay is a highly prognostic biomarker in early-stage triple negative breast cancer in another window
Includes: Supplementary data
Journal Articles

A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy

Patrick M. Grierson, Rama Suresh, Benjamin Tan, Katrina S. Pedersen, Manik Amin, Haeseong Park, Nikolaos A. Trikalinos, Jingxia Liu, Nicholas Boice, Amberly Brown, Sapana Bansod, Andrea Wang-Gillam, Kian-Huat Lim
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4733–4739.
https://doi.org/10.1158/1078-0432.CCR-23-1405
Published: 01 December 2023
View article titled, A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy
Open the PDF for A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy in another window
Includes: Supplementary data
Journal Articles

Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study

Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, Rama Suresh, Albert C. Lockhart, Amberly Brown, Marcus Breden, Jad I. Belle, John Herndon, Savannah J. Bogner, Katrina Pedersen, Benjamin Tan, Nicholas Boice, Abhi Acharya, Mina Abdiannia, Feng Gao, Harry H. Yoon, Mojun Zhu, Nikolaos A. Trikalinos, Lee Ratner, Olivia Aranha, William G. Hawkins, Brett H. Herzog, David G. DeNardo
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4698.
https://doi.org/10.1158/1078-0432.CCR-23-2993
Published: 14 November 2023
View article titled, Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study
Open the PDF for Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study in another window
Journal Articles

Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

Andrew A. Davis, Jingqin Luo, Tiantian Zheng, Chao Dai, Xiaoxi Dong, Lu Tan, Rama Suresh, Foluso O. Ademuyiwa, Caron Rigden, Timothy P. Rearden, Katherine Clifton, Katherine Weilbaecher, Ashley Frith, Pavan K. Tandra, Tracy Summa, Brittney Haas, Shana Thomas, Leonel F. Hernandez-Aya, Lindsay L. Peterson, Xiaohong Wang, Shujun J. Luo, Kemin Zhou, Pan Du, Shidong Jia, Bonnie L. King, Jairam Krishnamurthy, Cynthia X. Ma
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (9): 1719–1729.
https://doi.org/10.1158/1078-0432.CCR-22-2177
Published: 01 May 2023
View article titled, Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Open the PDF for Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, Rama Suresh, Albert C. Lockhart, Amberly Brown, Marcus Breden, Jad I. Belle, John Herndon, Savannah J. Bogner, Katrina Pedersen, Benjamin Tan, Nicholas Boice, Abhi Acharya, Mina Abdiannia, Feng Gao, Harry H. Yoon, Mojun Zhu, Nikolaos A. Trikalinos, Lee Ratner, Olivia Aranha, William G. Hawkins, Brett H. Herzog, David G. DeNardo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (24): 5254–5262.
https://doi.org/10.1158/1078-0432.CCR-22-0308
Published: 15 December 2022
View article titled, Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
Open the PDF for Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study in another window
Includes: Supplementary data
Journal Articles

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

Cynthia X. Ma, Feng Gao, Jingqin Luo, Donald W. Northfelt, Matthew Goetz, Andres Forero, Jeremy Hoog, Michael Naughton, Foluso Ademuyiwa, Rama Suresh, Karen S. Anderson, Julie Margenthaler, Rebecca Aft, Timothy Hobday, Timothy Moynihan, William Gillanders, Amy Cyr, Timothy J. Eberlein, Tina Hieken, Helen Krontiras, Zhanfang Guo, Michelle V. Lee, Nicholas C. Spies, Zachary L. Skidmore, Obi L. Griffith, Malachi Griffith, Shana Thomas, Caroline Bumb, Kiran Vij, Cynthia Huang Bartlett, Maria Koehler, Hussam Al-Kateb, Souzan Sanati, Matthew J. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4055–4065.
https://doi.org/10.1158/1078-0432.CCR-16-3206
Published: 01 August 2017
View article titled, NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
Open the PDF for NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

Cynthia X. Ma, Jingqin Luo, Michael Naughton, Foluso Ademuyiwa, Rama Suresh, Malachi Griffith, Obi L. Griffith, Zachary L. Skidmore, Nicholas C. Spies, Avinash Ramu, Lee Trani, Timothy Pluard, Gayathri Nagaraj, Shana Thomas, Zhanfang Guo, Jeremy Hoog, Jing Han, Elaine Mardis, Craig Lockhart, Matthew J. Ellis
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (7): 1583–1591.
https://doi.org/10.1158/1078-0432.CCR-15-1745
Published: 31 March 2016
View article titled, A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Open the PDF for A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer in another window
Includes: Supplementary data